The Ligandable Human Proteome

Aldo-keto reductase family 1 member C3

Index	Ligand Name	Structure	PDB code	ligand desolvation
1	imn	AKR1C3 complex with indomethacin at pH 6.8	3ugr	99.36
2	npx	AKR1C3 complex with R-naproxen	3ufy	99.25
3	imn	Crystal structures of prostaglandin D2 11-ketoreductase in complex with the non-steroidal anti-inflammatory drugs flufenamic acid and indomethacin	1s2a	98.96
4	0sz	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 in complex with 3-((3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)benzoic acid (17)	4fam	98.42
5	wdx	17beta-HSD5 in complex with [4-(2-hydroxyethyl)piperidin-1-yl](5-methyl-1H-indol-2-yl)methanone	4wdx	98.05
6	flr	AKR1C3 complex with flurbiprofen	3r94	97.95
7	nps	AKR1C3 complex with naproxen	3r58	97.94
8	0t0	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 in complex with 3-((3,4-dihydroisoquinolin-2(1H)-yl)sulfonyl)-N-methylbenzamide (80)	4fal	97.89
9	id8	AKR1C3 complexed with mefenamic acid	3r43	97.85
10	izp	AKR1C3 complex with ibuprofen	3r8g	97.81
11	511	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3) in complex with NADP+ and 2'-desmethyl-indomethacin	4dbw	97.64
12	ffw	Crystal structure of Aldo-Keto Reductase 1C3 (AKR1C3) complexed with inhibitor.	6gxk	96.93
13	jms	AKR1C3 complex with meclofenamic acid	3r6i	96.51
14	wdv	17beta-HSD5 in complex with 4-nitro-2-({4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}methyl)phenol	4xvd	96.46
15	imn	AKR1C3 complex with indomethacin at pH 7.5	3ug8	96.46
16	zom	AKR1C3 complex with zomepirac	3r8h	94.59
17	asd	Crystal structure of human 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3) complexed with delta4-androstene-3,17-dione and NADP	1xf0	93.98
18	wdu	17beta-HSD5 in complex with 4-chloro-N-(4-chlorobenzyl)-5-nitro-1H-pyrazole-3-carboxamide	4wdu	93.65
19	9s0	AKR1C3 complexed with new inhibitor with novel scaffold	6a7b	91.76
20	wds	17beta-HSD5 in complex with 3-pentyl-2-[(pyridin-2-ylmethyl)sulfanyl]-7-(pyrrolidin-1-ylcarbonyl)quinazolin-4(3H)-one	4xve	91.73
21	cj2	Potent and selective Aldo-Keto Reductase 1C3 (AKR1C3) inhibitors based on the benzoisoxazole moiety: application of a Bioisosteric Scaffold Hopping Approach to Flufenamic acid	6f2u	91.16
22	15m	Crystal structure of prostaglandin F synathase containing bimatoprost	2f38	90.86
23	e04	Crystal structure of human androgenic 17beta-hydroxysteroid dehydrogenase type 5 in complexed with a potent inhibitor EM1404	1zq5	90.75
24	qap	Crystal Structure of AKR1C3 complexed with CAPE	5hnt	90.38
25	pg2	Structure of prostaglandin F synthase with prostaglandin D2	1ry0	87.76
26	gmr	Crystal structure of AKR1C3 complexed with glimepiride	4yvx	87.46
27	gbm	Crystal structure of AKR1C3 complexed with glibenclamide	4yvv	82.59
28	gcz	Crystal structure of AKR1C3 complexed with glicazide	4zfc	81.29
29	suz	AKR1C3 complex with sulindac	3r7m	79.48
30	6ny	Crystal structure of AKR1C3 complexed with a pro-drug	5jm5	60.72